A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

Clinical trial NCT05662241 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05662241
Sponsor: Zenas BioPharma (USA), LLC
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

IgG4 Related Disease

Start date: 2023-01-09
Primary completion: 2025-11-13
Enrollment: 194

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.